Phage therapy of perinephric abscess in kidney transplantation recipients caused by drug-resistant Pseudomonas aeruginosa

References

[1] Haidar G, Green M. Intra-abdominal infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33:e13595.

[2] Hariharan S, Israni AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med. 2021; 385: 729–743.

[3] Lubetzky M, Tantisattamo E, Molnar MZ, Lentine KL, Basu A, Parsons RF, et al. The failing kidney allograft: a review and recommendations for the care and management of a complex group of patients. Am J Transplant. 2021; 21: 2937–2949.

[4] Santoro-Lopes G, Halpern M, Gonçalves RT. Perinephric abscess caused by Streptococcus agalactiae after renal transplantation. J Infect. 2005; 51: e145–e147.

[5] Edelstein HE, McCabe RE, Lieberman E. Perinephric abscess in renal transplant recipients: report of seven cases and review. Clin Infect Dis. 1989; 11: 569–577.

[6] Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther. 2022; 7: 199.

[7] Liu X, Jia M, Wang J, Cheng H, Cai Z, Yu Z, et al. Cell division factor ZapE regulates Pseudomonas aeruginosa biofilm formation by impacting the pqs quorum sensing system. mLife. 2023; 2: 28–42.

[8] Huang M, Liu L, Li X, Shi Y, Zhang H, Lu T, et al. Heterogeneity and clinical genomics of bla_KPC-2-producing, carbapenem-resistant Pseudomonas aeruginosa. hLife. 2024; 2: 314–319.

[9] Song Y, Mu Y, Wong N-K, Yue Z, Li J, Yuan M, et al. Emergence of hypervirulent Pseudomonas aeruginosa pathotypically armed with co-expressed T3SS effectors ExoS and ExoU. hLife. 2023; 1: 44–56.

[10] Little JS, Dedrick RM, Freeman KG, Cristinziano M, Smith BE, Benson CA, et al. Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nat Commun. 2022; 13: 2313.

[11] Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: from biological mechanisms to future directions. Cell. 2023; 186: 17–31.

[12] Suh GA, Ferry T, Abdel MP. Phage therapy as a novel therapeutic for the treatment of bone and joint infections. Clin Infect Dis. 2023; 77: S407–S415.

[13] Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health. 2018; 2018: 60–66.

[14] Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol. 2024; 9: 1434–1453.

[15] Maddocks S, Fabijan AP, Ho J, Lin RCY, Ben Zakour NL, Dugan C, et al. Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2019; 200: 1179–1181.

[16] Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022; 22: e208–e220.

[17] Law N, Logan C, Yung G, Furr CL, Lehman SM, Morales S, et al. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019; 47: 665–668.

[18] Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect Dis. 2020; 7:ofaa389.

[19] Van Nieuwenhuyse B, Van der Linden D, Chatzis O, Lood C, Wagemans J, Lavigne R, et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nat Commun. 2022; 13: 5725.

[20] Chegini Z, Khoshbayan A, Taati Moghadam M, Farahani I, Jazireian P, Shariati A. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Ann Clin Microbiol Antimicrob. 2020; 19: 45.

[21] Hu Q, Huang L, Yang Y, Xiang Y, Liu J. Essential phage component induces resistance of bacterial community. Sci Adv. 2024; 10:eadp5057.

[22] Hansen MF, Svenningsen SL, Røder HL, Middelboe M, Burmølle M. Big impact of the tiny: bacteriophage-bacteria interactions in biofilms. Trends Microbiol. 2019; 27: 739–752.

[23] Agrawal A, Ison MG, Danziger-Isakov L. Long-term infectious complications of kidney transplantation. Clin J Am Soc Nephrol. 2022; 17: 286–295.

[24] Nieto T, Inston N, Cockwell P. Renal transplantation in adults. BMJ. 2016; 355: i6158.

[25] Advocating for phage therapy. Nat Microbiol. 2024; 9: 1397–1398.

[26] Qin J, Wu N, Bao J, Shi X, Ou H, Ye S, et al. Heterogeneous Klebsiella pneumoniae co-infections complicate personalized bacteriophage therapy. Front Cell Infect Microbiol. 2020; 10:608402.

[27] Köhler T, Luscher A, Falconnet L, Resch G, McBride R, Mai QA, et al. Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa. Nat Commun. 2023; 14: 3629.

[28] Nick JA, Dedrick RM, Gray AL, Vladar EK, Smith BE, Freeman KG, et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022; 185: 1860–1874.e12.

[29] Loh B, Gondil VS, Manohar P, Khan FM, Yang H, Leptihn S. Encapsulation and delivery of therapeutic phages. Appl Environ Microbiol. 2021; 87:e01979-20.

[30] Chang RYK, Wallin M, Lin Y, Leung SSY, Wang H, Morales S, et al. Phage therapy for respiratory infections. Adv Drug Deliv Rev. 2018; 133: 76–86.

[31] Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 2017; 249: 100–133.

[32] Ferry T, Kolenda C, Laurent F, Leboucher G, Merabischvilli M, Djebara S, et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat Commun. 2022; 13: 4239.

[33] Li L, Zhong Q, Zhao Y, Bao J, Liu B, Zhong Z, et al. First-in-human application of double-stranded RNA bacteriophage in the treatment of pulmonary Pseudomonas aeruginosa infection. Microb Biotechnol. 2023; 16: 862–867.

[34] Le S, Wei L, Wang J, Tian F, Yang Q, Zhao J, et al. Bacteriophage protein Dap1 regulates evasion of antiphage immunity and Pseudomonas aeruginosa virulence impacting phage therapy in mice. Nat Microbiol. 2024; 9: 1828–1841.

[35] Zhong Q, Liao B, Liu J, Shen W, Wang J, Wei L, et al. Episymbiotic Saccharibacteria TM7x modulates the susceptibility of its host bacteria to phage infection and promotes their coexistence. Proc Natl Acad Sci USA. 2024; 121:e2319790121.

[36] Barrick JE, Colburn G, Deatherage DE, Traverse CC, Strand MD, Borges JJ, et al. Identifying structural variation in haploid microbial genomes from short-read resequencing data using breseq. BMC Genomics. 2014; 15: 1039.

[37] Jain C, Rodriguez-R LM, Phillippy AM, Konstantinidis KT, Aluru S High throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries. Nat Commun2018; 9: 5114.

RIGHTS & PERMISSIONS

2025 The Author(s). mLife published by John Wiley & Sons Australia, Ltd on behalf of Institute of Microbiology, Chinese Academy of Sciences.